DOCSLIB.ORG

Placental Growth Factor in Beta Cells Plays an Essential Role in Gestational Beta-­Cell Growth

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Placental Growth Factor in Beta Cells Plays an Essential Role in Gestational Beta-­Cell Growth Islet Studies BMJ Open Diab Res Care: first published as 10.1136/bmjdrc-2019-000921 on 5 March 2020. Downloaded from Open access Original research Placental growth factor in beta cells plays an essential role in gestational beta- cell growth Weixia Yang,1,2 Yinan Jiang,2 Yan Wang,2 Ting Zhang,2 Qun Liu,2,3 Chaoban Wang,2,4 Grant Swisher,2 Nannan Wu,2,5 Chelsea Chao,2 Krishna Prasadan,2 George K Gittes,2 Xiangwei Xiao 2 To cite: Yang W, Jiang Y, ABSTRACT Wang Y, et al. Placental Objective Pancreatic beta cells proliferate in response to Significance of this study growth factor in beta cells metabolic requirements during pregnancy, while failure of plays an essential role in this response may cause gestational diabetes. A member What is already known about this subject? gestational beta- cell growth. of the vascular endothelial growth factor family, placental ► The expression and function of placental growth fac- BMJ Open Diab Res Care growth factor (PlGF), typically plays a role in metabolic tor (PlGF) in the endocrine pancreas have not been 2020;8:e000921. doi:10.1136/ studied before. bmjdrc-2019-000921 disorder and pathological circumstance. The expression and function of PlGF in the endocrine pancreas have not What are the new findings? been reported and are addressed in the current study. ► PlGF is exclusively expressed by beta cells in adult Additional material is ► Research design and methods PlGF levels in beta cells pancreas. published online only. To view, were determined by immunostaining or ELISA in purified please visit the journal online ► Increased beta cell- derived PlGF promotes gesta- beta cells in non-pregnant and pregnant adult mice. An tional beta- cell growth through macrophages. (http:// dx. doi. org/ 10. 1136/ adeno- associated virus (AAV) serotype 8 carrying a shRNA bmjdrc- 2019- 000921). for PlGF under the control of a rat insulin promoter (AAV– How might these results change the focus of rat insulin promoter (RIP)–short hairpin small interfering research or clinical practice? Received 24 September 2019 RNA for PlGF (shPlGF)) was prepared and infused into ► The contribution of insufficient beta cell- derived Revised 28 January 2020 mouse pancreas through the pancreatic duct to specifically PlGF to the development of gestational diabetes de- Accepted 31 January 2020 knock down PlGF in beta cells, and its effects on beta-cell serves further investigation in the clinic. growth were determined by beta- cell proliferation, beta- cell mass and insulin release. A macrophage-depleting reagent, clodronate, was coapplied into AAV- treated mice type 2 diabetes, which occurs later in the life to study crosstalk between beta cells and macrophages. of pregnant women.3 Hence, understanding Results PlGF is exclusively produced by beta cells in http://drc.bmj.com/ the adult mouse pancreas. Moreover, PlGF expression in the etiology and pathogenesis of gestational beta cells was significantly increased during pregnancy. diabetes is extremely important, given that Intraductal infusion of AAV–RIP–shPlGF specifically this disease affects up to 10% of pregnant knocked down PlGF in beta cells, resulting in compromised women.4 beta- cell proliferation, reduced growth in beta- cell Studies on pregnant women and rodents mass and impaired glucose tolerance during pregnancy. have suggested that the gestational increases Mechanistically, PlGF depletion in beta cells reduced islet in insulin production and secretion by beta on September 24, 2021 by guest. Protected copyright. infiltration of trophic macrophages, which appeared to be cells may be largely attributable to beta- essential for gestational beta-cell growth. 5–10 Conclusions Our study suggests that increased cell growth during this period. Indeed, expression of PlGF in beta cells may trigger gestational numerous studies have shown that gesta- beta- cell growth through recruited macrophages. tional increase in beta-cell mass primarily stems from beta- cell proliferation.11–14 Failure to adequately increase beta-cell mass may © Author(s) (or their INTRODUCTION cause glucose intolerance or even gestational employer(s)) 2020. Re- use During pregnancy, the increase in maternal diabetes. To date, the molecular mechanisms permitted under CC BY-NC. No commercial re- use. See rights blood glucose requires the pancreas to underlying gestational beta-cell growth are 5–10 and permissions. Published produce more insulin to keep normal glucose not fully understood. by BMJ. homeostasis,1 and failure of this compen- The intimate relationship between beta cells For numbered affiliations see sation may cause gestational diabetes.2 and endothelial cells starts during embryonic end of article. Although the high blood sugar in gestational pancreatic organogenesis15 and plays a crit- Correspondence to diabetes usually returns to normal after preg- ical role in both endocrine pancreas develop- 16 Dr Xiangwei Xiao; nancy, previous studies have shown that gesta- ment and beta- cell function in adults. This xiangwei. xiao@ chp. edu tional diabetes is a predisposing factor for interaction is mainly mediated by vascular BMJ Open Diab Res Care 2020;8:e000921. doi:10.1136/bmjdrc-2019-000921 1 BMJ Open Diab Res Care: first published as 10.1136/bmjdrc-2019-000921 on 5 March 2020. Downloaded from Islet Studies endothelial growth factor A (VEGF- A), the best studied Harbor, Maine, USA). Tamoxifen induction of Tomato ligand from the vascular endothelial growth factor expression in acinar cells in Ela-CreER T; Tomato mice (VEGF) family.17 We have previously shown that VEGF-A has been described before.19 INS1cre knock- in mice were plays a role in the control of beta-cell mass in response bred with Tomato mice to generate INS1cre; Tomato mice to glucose alterations in the circulation,18 while the two for purification of beta- cells based on red fluorescence. major sources of VEGF-A in pancreas are beta cells and Fasting blood glucose monitoring and intraperitoneal duct cells, which differentially regulate VEGF- A release.19 glucose tolerance testing were performed as described These earlier studies contributed to our understanding before.21 Pancreatic intraductal virus infusion was of the role of VEGF- A in beta- cell biology. However, performed as described.24 Injection of 200 µL chlodro- VEGF family members other than VEGF- A biology have nate and control liposome (clodronate liposomes, Neth- been minimally studied in beta- cell biology. erlands) from the tail vein of the mice was performed Placental growth factor (PlGF) is another member of twice per week, starting 1 day before time breeding until the VEGF family and is thought to play a role in altered the end of the experiment, as previously described.21 metabolic states or under some pathological circum- stance.20 The expression and function of PlGF in the RNA isolation and quantitative reverse transcription PCR (RT- endocrine pancreas have not been examined. Here, we qPCR) investigated PlGF expression in beta cells, as well as its Total RNA was extracted using the RNeasy mini kit role in gestational beta- cell growth. (Qiagen, Valencia, California, USA) and then quanti- fied with the Nanodrop 1000 (Thermo Fisher Scien- tific, Waltham, Massachusetts, USA), followed by cDNA MATERIALS AND METHODS synthesis (Qiagen) and RT- qPCR. Primers for CycloA Production of AAV8 expressing shPlGF under a rat insulin (QT00247709) and PlGF (QT00103222) were both promoter (RIP) purchased from Qiagen. Relative values of mRNA levels A PlGF shRNA sequence ( GCTG TTCA CTTG CTTC TTAG were obtained by sequential normalization against the TCGA GTAA GAAG CAAG TGAACAGC) or a scramble ( housekeeping gene cyclophilin A and the experimental GCTG AGTA CTTC GAAA TGTC GTCG AGGA CATT TCGA control. AGTA CTCAGCG) was designed using Block- IT RNAi PlGF ELISA designer and was cloned into pAAV-mcherr y- flex- dtA PlGF levels were determined with a PlGF ELISA kit (R&D (dTA) (Addgene, No 58536, Cambridge, Massachusetts, Systems, Los Angeles, California, USA). All reagents, stan- USA) by restriction sites BsrG1 and SalI. A RIP described dard dilutions and samples were prepared as directed in before21 was swapped into the vector by restriction sites the product insert. First, 100 µL of Assay Diluent was added FseI and XbaI. Adeno- associated virus (AAV) serotype 8 to each well, followed by 100 µL of standard, control, or vectors were generated by cotransfection with the shPlGF sample to each well. The microplate was then covered or the scrambled plasmid, a packaging plasmid carrying with a plate sealer and incubated at room temperature rep and cap from the AAV serotype 8, and a helper for 2 hours. Each well was aspirated and washed three http://drc.bmj.com/ plasmid carrying the adenovirus helper in human embry- times, after which 200 µL of conjugate was added to each onic kidney 293 cells, as described before.22 AAV viruses well. The microplate was then covered with a new plate were purified by polyethylene glycol/aqueous two-phase sealer and incubated at room temperature for 1 hour partitioning and then stored at −80°C for later use. before another four times of aspiration and wash. Finally, Titration of viral vectors was determined by an AAVpro 200 µL substrate solution was added to each well, and Titration kit (TaKaRa Bio, Mountain View, California, the microplate was incubated at room temperature for on September 24, 2021 by guest. Protected copyright. USA). Recombinant mouse PlGF was purchased from 30 min before 50 µL of stop solution was added to each Abcam (Ab207150, Cambridge, Massachusetts, USA) well. The microplate was read at 450 nm within 30 min. and was delivered to mice via pancreatic duct at 20 µg/ The wavelength correction was set to 540 or 570 nm. mouse. The control mice received saline. Transfection of a beta- cell line Min6 (American Type Culture Collection, Pancreatic digestion and FACS Rockville, Maryland, USA) was performed using Lipo- Pancreatic duct perfusion, pancreas digestion, islet isola- fectamine 3000 (Invitrogen, Carlsbad, California, USA).
Load more

Recommended publications
  • Insulin Sensitivity and ß-Cell Function in Women with Polycystic Ovary
    Pathophysiology/Complications ORIGINAL ARTICLE Insulin Sensitivity and ␤-Cell Function in Women With Polycystic Ovary Syndrome JANA VRB´IKOVA´, MD MARKETA´ VANKOVA´, MS found defective insulin secretion (9–11), BELA BENDLOVA´, PHD KAREL VONDRA, MD whereas others have described an in- MARTIN HILL, PHD LUBOSLAV STARKA´ , MD, DSC crease of insulin secretion (12,13). In the present study, IS and ␤-cell function (␤F) in lean (BMI Ͻ27 kg/m2) and obese (BMI Ն27 kg/m2) women with PCOS were studied using oral glucose tol- ␤ ␤ OBJECTIVE — To evaluate insulin sensitivity (IS) and -cell function ( F) in lean and obese erance tests (OGTTs) and insulin toler- women with polycystic ovary syndrome (PCOS), either separately or by using a disposition index ance tests (ITTs) as methods available in (DI). daily practice. The authors have tried to evaluate PCOS women in terms of IS RESEARCH DESIGN AND METHODS — A total of 64 women with PCOS and 20 and/or ␤F either separately or by the tool healthy women were examined by anthropometry, oral glucose tolerance tests (OGTTs), and insulin tolerance tests. Statistical analysis used one-way ANOVA, Kruskal-Wallis, and Mann- of disposition index (DI), which could be Whitney U tests, as appropriate. more informative than isolated evalua- tions of IS and ␤F. RESULTS — A significantly higher waist-to-hip ratio (P Ͻ 0.0001) was found in both lean and obese women with PCOS. Higher basal blood glucose (P Ͻ 0.004) and blood glucose values at RESEARCH DESIGN AND 3 h of OGTT (P Ͻ 0.008) were found in lean and obese PCOS subjects in comparison with METHODS — In all, 64 women with control subjects.
    [Show full text]
  • Endocrine Cell Type Sorting and Mature Architecture in the Islets Of
    www.nature.com/scientificreports OPEN Endocrine cell type sorting and mature architecture in the islets of Langerhans require expression of Received: 16 April 2018 Accepted: 4 July 2018 Roundabout receptors in β cells Published: xx xx xxxx Melissa T. Adams, Jennifer M. Gilbert, Jesus Hinojosa Paiz, Faith M. Bowman & Barak Blum Pancreatic islets of Langerhans display characteristic spatial architecture of their endocrine cell types. This architecture is critical for cell-cell communication and coordinated hormone secretion. Islet architecture is disrupted in type-2 diabetes. Moreover, the generation of architecturally correct islets in vitro remains a challenge in regenerative approaches to type-1 diabetes. Although the characteristic islet architecture is well documented, the mechanisms controlling its formation remain obscure. Here, we report that correct endocrine cell type sorting and the formation of mature islet architecture require the expression of Roundabout (Robo) receptors in β cells. Mice with whole-body deletion of Robo1 and conditional deletion of Robo2 either in all endocrine cells or selectively in β cells show complete loss of endocrine cell type sorting, highlighting the importance of β cells as the primary organizer of islet architecture. Conditional deletion of Robo in mature β cells subsequent to islet formation results in a similar phenotype. Finally, we provide evidence to suggest that the loss of islet architecture in Robo KO mice is not due to β cell transdiferentiation, cell death or loss of β cell diferentiation or maturation. Te islets of Langerhans display typical, species-specifc architecture, with distinct spatial organization of their various endocrine cell types1–5. In the mouse, the core of the islet is composed mostly of insulin-secreting β cells, while glucagon-secreting α cells, somatostatin-secreting δ cells and pancreatic polypeptide-secreting PP cells are located at the islet periphery3.
    [Show full text]
  • The Role of Thyroid Hormone
    Central Journal of Endocrinology, Diabetes & Obesity Mini Review Special Issue on Role of Thyroid Hormone Pancreatic and Islet Develop- in Metabolic Homeostasis ment and Function: The Role of *Corresponding authors Teresa L Mastracci, Department of Pediatrics, Indiana University School of Medicine, Herman B Wells Center for Thyroid Hormone Pediatric Research, 635 Barnhill Dr, MS2031, Indianapolis, IN, USA 46202, Tel: 317-278-8940; Fax: 317-274-4107; Teresa L Mastracci1,5* and Carmella Evans-Molina2,3,4,5* Email: 1Department of Pediatrics, Indiana University School of Medicine, USA Carmella Evans-Molina, Department of Medicine, 2Department of Medicine, Indiana University School of Medicine, USA Cellular and Integrative Physiology, Biochemistry and 3Department of Cellular and Integrative Physiology, Indiana University School of Molecular Biology, Herman B Wells Center for Pediatric Medicine, USA Research, Indiana University School of Medicine, 4Department of Biochemistry and Molecular Biology, Indiana University School of Indiana University School of Medicine, 635 Barnhill Dr., Medicine, USA MS2031, Indianapolis, IN, USA 46202, Tel: 317-278-3177; 5Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Fax: 317-274-4107; Email: USA Submitted: 12 June 2014 Accepted: 17 July 2014 Published: 19 July 2014 Abstract ISSN: 2333-6692 A gradually expanding body of literature suggests that Thyroid Hormone (TH) Copyright and Thyroid Hormone Receptors (TRs) play a contributing role in pancreatic and islet © 2014 Mastracci et al. cell development, maturation, and function. Studies using a variety of model systems capable of exploiting species-specific developmental paradigms have revealed the OPEN ACCESS contribution of TH to cellular differentiation, lineage decisions, and endocrine cell specification.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0111743 A1 Takahashi (43) Pub
    US 200901 11743A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0111743 A1 Takahashi (43) Pub. Date: Apr. 30, 2009 (54) CYSTEINE-BRANCHED HEPARIN-BINDING Related U.S. Application Data GROWTH FACTOR ANALOGS (60) Provisional application No. 60/656,713, filed on Feb. 25, 2005. (75) Inventor: Kazuyuki Takahashi, O O Germantown, MD (US) Publication Classification (51) Int. Cl. Correspondence Address: A638/08C07K 700 30.82006.O1 201 THIRD STREET, N.W., SUITE 1340 A638/16 (2006.01) ALBUQUEROUE, NM 87102 (US) A638/10 (2006.01) A638/00 (2006.01) (73) Assignee: BioSurface Engineering (52) U.S. Cl. ........... 514/12:530/330; 530/329; 530/328; Technologies, Inc., Rockville, MD 530/327: 530/326; 530/325; 530/324; 514/17; (US) 514/16; 514/15: 514/14: 514/13 (57) ABSTRACT (21) Appl. No.: 11/362,137 The present invention provides a heparin binding growth factor analog of any of formula I-VIII and methods and uses (22) Filed: Feb. 23, 2006 thereof. US 2009/011 1743 A1 Apr. 30, 2009 CYSTENE-BRANCHED HEPARN-BINDING 0007 HBGFs useful in prevention or therapy of a wide GROWTH FACTOR ANALOGS range of diseases and disorders may be purified from natural sources or produced by recombinant DNA methods, however, CROSS-REFERENCE TO RELATED Such preparations are expensive and generally difficult to APPLICATIONS prepare. 0008. Some efforts have been made to generate heparin 0001. This application claims priority to and the benefit of binding growth factor analogs. For example, natural PDGF the filing of U.S. Provisional Patent Application Ser.
    [Show full text]
  • Angiocrine Endothelium: from Physiology to Cancer Jennifer Pasquier1,2*, Pegah Ghiabi2, Lotf Chouchane3,4,5, Kais Razzouk1, Shahin Rafi3 and Arash Rafi1,2,3
    Pasquier et al. J Transl Med (2020) 18:52 https://doi.org/10.1186/s12967-020-02244-9 Journal of Translational Medicine REVIEW Open Access Angiocrine endothelium: from physiology to cancer Jennifer Pasquier1,2*, Pegah Ghiabi2, Lotf Chouchane3,4,5, Kais Razzouk1, Shahin Rafi3 and Arash Rafi1,2,3 Abstract The concept of cancer as a cell-autonomous disease has been challenged by the wealth of knowledge gathered in the past decades on the importance of tumor microenvironment (TM) in cancer progression and metastasis. The sig- nifcance of endothelial cells (ECs) in this scenario was initially attributed to their role in vasculogenesis and angiogen- esis that is critical for tumor initiation and growth. Nevertheless, the identifcation of endothelial-derived angiocrine factors illustrated an alternative non-angiogenic function of ECs contributing to both physiological and pathological tissue development. Gene expression profling studies have demonstrated distinctive expression patterns in tumor- associated endothelial cells that imply a bilateral crosstalk between tumor and its endothelium. Recently, some of the molecular determinants of this reciprocal interaction have been identifed which are considered as potential targets for developing novel anti-angiocrine therapeutic strategies. Keywords: Angiocrine, Endothelium, Cancer, Cancer microenvironment, Angiogenesis Introduction of blood vessels in initiation of tumor growth and stated Metastatic disease accounts for about 90% of patient that in the absence of such angiogenesis, tumors can- mortality. Te difculty in controlling and eradicating not expand their mass or display a metastatic phenotype metastasis might be related to the heterotypic interaction [7]. Based on this theory, many investigators assumed of tumor and its microenvironment [1].
    [Show full text]
  • Type of the Paper (Article
    Table S1. Gene expression of pro-angiogenic factors in tumor lymph nodes of Ibtk+/+Eµ-myc and Ibtk+/-Eµ-myc mice. Fold p- Symbol Gene change value 0,007 Akt1 Thymoma viral proto-oncogene 1 1,8967 061 0,929 Ang Angiogenin, ribonuclease, RNase A family, 5 1,1159 481 0,000 Angpt1 Angiopoietin 1 4,3916 117 0,461 Angpt2 Angiopoietin 2 0,7478 625 0,258 Anpep Alanyl (membrane) aminopeptidase 1,1015 737 0,000 Bai1 Brain-specific angiogenesis inhibitor 1 4,0927 202 0,001 Ccl11 Chemokine (C-C motif) ligand 11 3,1381 149 0,000 Ccl2 Chemokine (C-C motif) ligand 2 2,8407 298 0,000 Cdh5 Cadherin 5 2,5849 744 0,000 Col18a1 Collagen, type XVIII, alpha 1 3,8568 388 0,003 Col4a3 Collagen, type IV, alpha 3 2,9031 327 0,000 Csf3 Colony stimulating factor 3 (granulocyte) 4,3332 258 0,693 Ctgf Connective tissue growth factor 1,0195 88 0,000 Cxcl1 Chemokine (C-X-C motif) ligand 1 2,67 21 0,067 Cxcl2 Chemokine (C-X-C motif) ligand 2 0,7507 631 0,000 Cxcl5 Chemokine (C-X-C motif) ligand 5 3,921 328 0,000 Edn1 Endothelin 1 3,9931 042 0,001 Efna1 Ephrin A1 1,6449 601 0,002 Efnb2 Ephrin B2 2,8858 042 0,000 Egf Epidermal growth factor 1,726 51 0,000 Eng Endoglin 0,2309 467 0,000 Epas1 Endothelial PAS domain protein 1 2,8421 764 0,000 Ephb4 Eph receptor B4 3,6334 035 V-erb-b2 erythroblastic leukemia viral oncogene homolog 2, 0,000 Erbb2 3,9377 neuro/glioblastoma derived oncogene homolog (avian) 024 0,000 F2 Coagulation factor II 3,8295 239 1 0,000 F3 Coagulation factor III 4,4195 293 0,002 Fgf1 Fibroblast growth factor 1 2,8198 748 0,000 Fgf2 Fibroblast growth factor
    [Show full text]
  • Targeting Fibroblast Growth Factor Pathways in Endometrial Cancer
    Curr Probl Cancer 41 (2017) 37–47 Contents lists available at ScienceDirect Curr Probl Cancer journal homepage: www.elsevier.com/locate/cpcancer Targeting fibroblast growth factor pathways in endometrial cancer Boris Winterhoff, MDa, Gottfried E. Konecny, MDb,* article info abstract Novel treatments that improve outcomes for patients with Keywords: recurrent or metastatic endometrial cancer (EC) remain an Endometrial cancer unmet need. Aberrant signaling by fibroblast growth factors Fibroblast growth factor (FGFs) and FGF receptors (FGFRs) has been implicated in Angiogenesis several human cancers. Activating mutations in FGFR2 have been found in up to 16% of ECs, suggesting an opportunity for targeted therapy. This review summarizes the role of the FGF pathway in angiogenesis and EC, and provides an overview of FGFR-targeted therapies under clinical develop- ment for the treatment of EC. & 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Introduction Endometrial cancer (EC) is the most common gynecologic cancer, with 54,870 new cases and 10,170 related deaths estimated for the United States in 2015.1 Localized disease is often curable with surgery and the 5-year relative survival rate for patients diagnosed with early-stage EC is high.1-3 However, for patients who present with metastatic disease or experience a recurrence, prognosis is poor.1-3 Response of metastatic EC to standard therapies (eg, adjuvant radiotherapy, brachytherapy, or chemotherapy) is limited and overall survival for most patients with recurrent or metastatic disease is r1year.2-4 Thus, novel treatment options for this disease remain an unmet need.
    [Show full text]
  • Investigating Hypoxic Tumor Physiology Through Gene Expression Patterns
    Oncogene (2003) 22, 5907–5914 & 2003 Nature Publishing Group All rights reserved 0950-9232/03 $25.00 www.nature.com/onc Investigating hypoxic tumor physiology through gene expression patterns Nicholas C Denko*,1, Lucrezia A Fontana1, Karen M Hudson1, Patrick D Sutphin1, Soumya Raychaudhuri2, Russ Altman2 and Amato J Giaccia1 1Division of Radiation and Cancer Biology, Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA; 2Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA Clinical evidence shows that tumor hypoxia is an relyupon oxygen-dependent energyproduction suffer independent prognostic indicator of poor patient outcome. when oxygen falls below a certain threshold level. Hypoxic tumors have altered physiologic processes, However, too much oxygen can also result in the including increased regions of angiogenesis, increased generation of toxic, damaging radical byproducts. The local invasion, increased distant metastasis and altered net effect of these opposing pressures necessitates apoptotic programs. Since hypoxia is a potent controller the evolution of molecular mechanisms to regulate the of gene expression, identifying hypoxia-regulated genes is cellular availabilityand usage of oxygen. a means to investigate the molecular response to hypoxic The response to low-oxygen conditions has been stress. Traditional experimental approaches have identi- identified in both procaryotes and eucaryotes. Although fied physiologic changes in hypoxic cells. Recent studies the mechanisms for gene regulation in response to low- have identified hypoxia-responsive genes that may define oxygen conditions are diverse, parallel systems have the mechanism(s) underlying these physiologic changes. evolved in different organisms that are transcriptionally For example, the regulation of glycolytic genes by responsive to low-oxygen.
    [Show full text]
  • First Responder Cells Drive the First-Phase [Ca2+] Response
    bioRxiv preprint doi: https://doi.org/10.1101/2020.12.22.424082; this version posted December 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Functional architecture of the pancreatic islets: First responder cells drive the first-phase [Ca2+] response Vira Kravetsa,b, JaeAnn M. Dwuleta, Wolfgang E. Schleicherb, David J. Hodsonc, Anna M. Davis,a Robert A. Piscopiob, Maura Sticco-Ivins,b Richard K.P. Benningera,b,1. a Department of Bioengineering, University of Colorado, Anschutz Medical campus, Aurora, CO. USA b Barbara Davis center for childhood diabetes, University of Colorado, Anschutz Medical campus, Aurora, CO. USA c Institute of Metabolism and Systems Research, University of Birmingham, Birmingham. UK, and Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, UK 1 To whom correspondence should be addressed: [email protected] Tel: (303) 724-6388. Fax: (303) 724-5800. 1775 Aurora court, M20-4306D, mailstop B140, University of Colorado Anschutz Medical campus, Aurora, CO. 80045. Short title: First responder cells control islet function Keywords: Laser ablation; Multicellular Dynamics; Biological Networks; Optical Microscopy; Diabetes; Gap junctions. Manuscript word count (main text, excluding methods): 5311. Abstract word count: 294 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.22.424082; this version posted December 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Insulin-secreting b-cells are functionally heterogeneous. Subpopulations of b-cells can control islet function and the regulation of hormone release, such as driving the second (oscillatory) phase of free-calcium ([Ca2+]) following glucose elevation.
    [Show full text]
  • GLIS3 Is Indispensable for TSH/TSHR-Dependent Thyroid Hormone Biosynthesis and Follicular Cell Proliferation
    GLIS3 is indispensable for TSH/TSHR-dependent thyroid hormone biosynthesis and follicular cell proliferation Hong Soon Kang, … , Raja Jothi, Anton M. Jetten J Clin Invest. 2017;127(12):4326-4337. https://doi.org/10.1172/JCI94417. Research Article Endocrinology Deficiency in Krüppel-like zinc finger transcription factor GLI-similar 3 (GLIS3) in humans is associated with the development of congenital hypothyroidism. However, the functions of GLIS3 in the thyroid gland and the mechanism by which GLIS3 dysfunction causes hypothyroidism are unknown. In the current study, we demonstrate that GLIS3 acts downstream of thyroid-stimulating hormone (TSH) and TSH receptor (TSHR) and is indispensable for TSH/TSHR- mediated proliferation of thyroid follicular cells and biosynthesis of thyroid hormone. Using ChIP-Seq and promoter analysis, we demonstrate that GLIS3 is critical for the transcriptional activation of several genes required for thyroid hormone biosynthesis, including the iodide transporters Nis and Pds, both of which showed enhanced GLIS3 binding at their promoters. The repression of cell proliferation of GLIS3-deficient thyroid follicular cells was due to the inhibition of TSH-mediated activation of the mTOR complex 1/ribosomal protein S6 (mTORC1/RPS6) pathway as well as the reduced expression of several cell division–related genes regulated directly by GLIS3. Consequently, GLIS3 deficiency in a murine model prevented the development of goiter as well as the induction of inflammatory and fibrotic genes during chronic elevation of circulating TSH. Our study identifies GLIS3 as a key regulator of TSH/TSHR-mediated thyroid hormone biosynthesis and proliferation of thyroid follicular cells and uncovers a mechanism by which GLIS3 deficiency causes neonatal hypothyroidism and prevents goiter development.
    [Show full text]
  • Endothelial Cells and VEGF in Vascular Development Leigh Coultas1, Kallayanee Chawengsaksophak1 & Janet Rossant1
    Insight Rossant p7-15 6/12/05 10:23 AM Page 9377 INSIGHT REVIEW NATURE|Vol 438|15 December 2005|doi:10.1038/nature04479 Endothelial cells and VEGF in vascular development Leigh Coultas1, Kallayanee Chawengsaksophak1 & Janet Rossant1 The intricate patterning processes that establish the complex vascular system during development depend on a combination of intrinsic pre-patterning and extrinsic responses to environmental parameters. Mutational studies in mice and fish have shown that the vascular system is highly sensitive to genetic disruption and have identified potential targets for therapeutic interventions. New insights into non-vascular roles of vascular endothelial growth factor and the requirement for endothelial cells in adult organs and stem- cell niches highlight possible side effects of anti-angiogenic therapy and the need for new targets. The development of the vascular system is one of the earliest events are essential for vascular development has been compiled and is in organogenesis. The early blood vessels of the embryo and yolk given in Supplementary Table 1. sac in mammals develop by aggregation of de-novo-forming Endothelial cells might probably have more interesting roles than angioblasts into a primitive vascular plexus (vasculogenesis), just acting as channels for blood circulation. They can promote stem- which then undergoes a complex remodelling process, in which cell development and organ formation by acting as sources of growth, migration, sprouting and pruning lead to the development of a functional circulatory system (angiogenesis; Fig. 1). Many of the events that occur during the normal progression of vascular development in the embryo are recapitulated during situations of neoangiogenesis in the adult1.
    [Show full text]
  • Beta Cell Physiological Dynamics and Dysfunctional Transitions in Response to Islet Inflammation in Obesity and Diabetes
    H OH metabolites OH Review Beta Cell Physiological Dynamics and Dysfunctional Transitions in Response to Islet Inflammation in Obesity and Diabetes Marlon E. Cerf 1,2,3 1 Grants, Innovation and Product Development, South African Medical Research Council, Tygerberg 7505, South Africa; [email protected] 2 Biomedical Research and Innovation Platform, South African Medical Research Council, Tygerberg 7505, South Africa 3 Division of Medical Physiology, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, University of Stellenbosch, Tygerberg 7505, South Africa Received: 14 August 2020; Accepted: 10 October 2020; Published: 10 November 2020 Abstract: Beta cells adapt their function to respond to fluctuating glucose concentrations and variable insulin demand. The highly specialized beta cells have well-established endoplasmic reticulum to handle their high metabolic load for insulin biosynthesis and secretion. Beta cell endoplasmic reticulum therefore recognize and remove misfolded proteins thereby limiting their accumulation. Beta cells function optimally when they sense glucose and, in response, biosynthesize and secrete sufficient insulin. Overnutrition drives the pathogenesis of obesity and diabetes, with adverse effects on beta cells. The interleukin signaling system maintains beta cell physiology and plays a role in beta cell inflammation. In pre-diabetes and compromised metabolic states such as obesity, insulin resistance, and glucose intolerance, beta cells biosynthesize and secrete more insulin, i.e., hyperfunction. Obesity is entwined with inflammation, characterized by compensatory hyperinsulinemia, for a defined period, to normalize glycemia. However, with chronic hyperglycemia and diabetes, there is a perpetual high demand for insulin, and beta cells become exhausted resulting in insufficient insulin biosynthesis and secretion, i.e., they hypofunction in response to elevated glycemia.
    [Show full text]